Targeting Alpha-Synuclein for the Treatment of Parkinson’s Disease

Author(s): Troy T. Rohn

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 11 , Issue 2 , 2012

Become EABM
Become Reviewer
Call for Editor


Parkinson’s disease (PD) is characterized as a neurodegenerative movement disorder presenting with rigidity, resting tremor, disturbances in balance and slowness in movement. An important pathologic feature of PD is the presence of Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons and which may play a role in synaptic plasticity and neurotransmission. Numerous studies suggest the aggregation and modification of alpha-synuclein as a key step leading to Lewy body formation and neuronal cell loss associated with PD. Because of the central role of alpha-synuclein in PD, it represents a novel drug target for the possible treatment of this disease. In this review, an overview of the role of alpha-synuclein in PD will be discussed with an emphasis on recent studies utilizing an immunization approach against alpha-synuclein as a possible treatment option for this debilitating disease.

Keywords: Alpha-synuclein, Immunization, Immunotherapy, Lewy Bodies, Parkinson's Disease, Toxins, Virus, SNpc, Alpha synuclein Fibrils, Dementia, Alzheimers disease, Active Immunization

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 24 April, 2012
Page: [174 - 179]
Pages: 6
DOI: 10.2174/187152712800269678
Price: $65

Article Metrics

PDF: 40